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Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely recommended and prescribed to treat pain in osteoarthritis. 
While measured to have a moderate effect on pain in osteoarthritis, NSAIDs have been associated with wide-ranging adverse 
events affecting the gastrointestinal, cardiovascular, and renal systems. Gastrointestinal toxicity is found with all NSAIDs, 
which may be of particular concern when treating older patients with osteoarthritis, and gastric adverse events may be reduced 
by taking a concomitant gastroprotective agent, although intestinal adverse events are not ameliorated. Cardiovascular toxicity 
is associated with all NSAIDs to some extent and the degree of risk appears to be pharmacotherapy specific. An increased 
risk of acute myocardial infarction and heart failure is observed with all NSAIDs, while an elevated risk of hemorrhagic 
stroke appears to be restricted to the use of diclofenac and meloxicam. All NSAIDs have the potential to induce acute kidney 
injury, and patients with osteoarthritis with co-morbid conditions including hypertension, heart failure, and diabetes mellitus 
are at increased risk. Osteoarthritis is associated with excess mortality, which may be explained by reduced levels of physical 
activity owing to lower limb pain, presence of comorbid conditions, and the adverse effects of anti-osteoarthritis medications 
especially NSAIDs. This narrative review of recent literature identifies data on the safety of non-selective NSAIDs to better 
understand the risk:benefit of using NSAIDs to manage pain in osteoarthritis.
Key Points 
Although effective against inflammatory-mediated 
pain, non-steroidal anti-inflammatory drugs are associ-
ated with multiple class-specific toxicities affecting 
the gastrointestinal, cardiovascular, and renal systems. 
Some adverse effects are related to the class mechanism 
of action, while others appear to be pharmacotherapy 
specific.
The choice of any agent should be considered on an indi-
vidual patient basis in osteoarthritis to provide adequate 
symptom relief while minimizing unwanted side effects.
1 Introduction
Oral non-steroidal anti-inflammatory drugs (NSAIDs) are 
universally recommended in international and national 
guidelines for the management of pain in osteoarthritis (OA) 
in patients presenting with severe pain and musculoskeletal 
pain, and those who are unresponsive to merely paracetamol 
(acetaminophen) [1–5]. Non-steroidal anti-inflammatory 
drugs are one of the most widely used drugs in OA: over 
50% of patients with OA in USA are prescribed NSAIDs, 
and among patients with OA across Europe using prescrip-
tion medications (47%), 60% of those received NSAIDs 
[6, 7]. Non-prescription NSAIDs were the most frequently 
reported medications (27%) used by participants in the Oste-
oarthritis Initiative with symptomatic radiographic knee OA, 
even for those aged > 75 years [8]. While there was a reduc-
tion in prescription NSAID use in the older population, in 
line with recommendations that oral NSAIDs should not be 
prescribed to those aged older than 75 years [9], the use of 
over-the-counter NSAIDs remained worryingly high in this 
age group [8].
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Non-steroidal anti-inflammatory drugs have a moderate 
effect on pain in OA, measured as an effect size of 0.37 (95% 
confidence interval [95% CI] 0.26–0.40) in a meta-analysis 
of ten randomized controlled trials (RCTs) of short-term 
treatment lasting for 6–12 weeks [10]. Although effective, 
a systematic literature review and meta-analysis up to 2011 
found an increased risk of serious gastrointestinal (GI), car-
diovascular (CV), and renal harms with NSAIDs compared 
with placebo [11]. Older patients have an increased risk of 
these adverse events (AEs) and are more likely to receive 
polypharmacy that can potentially interact with NSAIDs 
[12]. Older patients are more likely to have CV disease and 
age-related decline in renal function, increasing the risk 
of CV, hematologic, and renal AEs. In evaluation of the 
relative efficacy and safety of NSAIDs, guidelines for the 
non-surgical management of knee OA from the Osteoar-
thritis Research Society International consider the use of 
oral non-selective NSAIDs (nsNSAIDs) appropriate in indi-
vidual patients with OA without comorbidities, but uncertain 
in individuals with a moderate co-morbidity risk and not 
appropriate for individuals with a high co-morbidity risk 
[2]. In addition, management guidelines from the European 
Society for Clinical and Economic Aspects of Osteoporosis, 
Osteoarthritis, and Musculoskeletal Diseases recommend 
that NSAID use be limited to the lowest effective dose for 
the shortest time necessary to control symptoms, either 
intermittently or in longer cycles rather than in long-term 
use [1, 13]. Topical NSAIDs may be used in preference to 
oral NSAIDs particularly in patients aged ≥ 75 years as they 
are demonstrated to have similar efficacy to the oral medica-
tions with a reduced risk of systemic AEs [1, 13].
In this narrative literature review, we have identified data 
on the safety of traditional nsNSAIDs (naproxen, ibupro-
fen, diclofenac) published since the Cochrane review of 
2011 [11], to identify current understanding on the relative 
risk:benefit of the use of nsNSAIDs to manage pain in OA. 
We discuss the safety of cyclo-oxygenase (COX)-2 inhibitors 
as a specific class of NSAIDs (e.g., celecoxib, rofecoxib) in 
relation to the safety of nsNSAIDs, and in more detail as the 
subject of a separate systematic literature review and meta-
analysis, which is presented in the subsequent article of this 
supplement [14].
2  Mortality in Osteoarthritis
There is evidence for an increase in all-cause mortality and 
CV mortality in patients with lower limb OA, which is more 
pronounced in studies including symptomatic patients. A 
systematic review of mortality in OA, which found seven 
studies that provided data on either mortality or survival 
in people with OA, identified an overall increase in mor-
tality among persons with OA compared with the general 
population [15]. Risk factors for mortality in people with 
OA were identified as age, polyarticular disease, and comor-
bidities. Increased cause-specific mortality from CV and GI 
disorders was observed in some studies. Possible explana-
tions for the excess mortality in OA include reduced levels 
of physical activity owing to lower limb OA, the presence of 
comorbid conditions such as CV disease, as well as adverse 
effects of medications, particularly NSAIDs [15–20].
A recent population-based cohort study of general prac-
tice in the UK identified 1163 patients (aged > 35 years) with 
symptoms and radiologic confirmation of OA of the knee or 
hip, with a median follow-up of 14 years [21, 22]. Patients 
with OA were found to be at a higher risk of death compared 
with the general population. Excess mortality was observed 
for all disease-specific causes of death (standardized mortal-
ity ratio = 1.55, 95% CI 1.41–1.70), but was particularly pro-
nounced for CV causes (standardized mortality ratio = 1.71, 
95% CI 1.49–1.98) [21]. Mortality was found to increase 
with age, male sex, co-morbidity (diabetes mellitus, cancer, 
CV disease), and walking disability. The more severe the 
walking disability, the higher the risk of death [21, 23].
The association of knee OA with premature mortality in 
the community has been assessed in an international meta-
analysis of data from individual participant data included in 
six prospective population-based cohorts [24]. Subjects were 
divided into four knee OA categories depending on the pres-
ence of radiographic OA and/or symptomatic OA, with or 
without pain. Subjects with knee symptomatic radiographic 
OA had a significant 19% increased association with prema-
ture mortality independent of age, sex, and race, compared 
with subjects free from OA (hazard ratio [HR] = 1.19, 95% 
CI 1.04–1.37) [24].
In another systematic review with a meta-analysis, the 
risk of all-cause and CV mortality was assessed using 
adjusted HRs for joint specific (hand, hip, and knee) and 
joint non-specific OA [25]. The meta-analysis of seven stud-
ies (OA = 10,018/non-OA = 18,541) with a median 12-year 
follow-up, reported no increased risk of any-cause mortality 
in those with OA (HR = 1.10, 95% CI 0.97–1.25). However, 
after removing data on hand OA, a significant association 
between OA and mortality was observed (HR = 1.18, 95% 
CI 1.08–1.28). In addition, the analysis found a significant 
higher risk of overall mortality for (1) studies conducted in 
Europe, (2) patients with multi-joint OA; and (3) a radio-
logic diagnosis of OA. Osteoarthritis was associated with 
significantly higher CV mortality (HR = 1.21, 95% CI 
1.10–1.34) [25]. Painful knee but not hand OA is associated 
with an increased risk of all-cause mortality and CV mortal-
ity, suggesting that knee pain more than structural changes 
in OA is the main driver of excess mortality in patients with 
OA [26]. Although hand OA is not linked with mortality, 
symptomatic hand OA is associated with an increased risk 
of coronary heart disease (HR = 2.26, 95% CI 1.22–4.18), 
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which suggest an effect of pain, which may be a possible 
marker of inflammation [27]. Furthermore, coronary heart 
disease is associated with a worse clinical outcome for hand 
OA over 2.6 years (odds ratio = 2.91, 95% CI 1.02–8.26), 
as identified in a post-hoc analysis of patients included in a 
phase III randomized trial of strontium ranelate [28].
3  Non‑Steroidal Anti‑Inflammatory Drugs: 
Mechanism of Action and Potential 
for Adverse Events
Non-steroidal anti-inflammatory drugs exert their effects 
by inhibiting the COX enzymes, which are the first step in 
the conversion of arachidonic acid into various prostaglan-
dins, thromboxanes, and prostacyclins. Two main isoforms 
of COX enzymes exist: COX-1 and COX-2. Cyclo-oxyge-
nase-1 is constitutively expressed in many tissues and physi-
ologically functions in the maintenance of renal function, 
protection of the gastric mucosa, and in the regulation of 
platelet aggregation. Cyclo-oxygenase-2 is considered to be 
inducible by proinflammatory cytokines and growth factors. 
The use of nsNSAIDs is limited by AEs associated with 
inhibition of the COX-1 enzyme, particularly GI ulcers and 
bleeding (Fig. 1) [29].
Thus, selective COX-2 inhibitors were designed to reduce 
the GI toxicity associated with nsNSAIDs; however, they 
may have a higher incidence of CV toxicity by altering the 
normal balance in the production of prostacyclin vs. throm-
boxane by different cell types in the CV system. There is 
also evidence from animal studies of a difference between 
NSAIDs in direct toxicity on the heart via reactive oxy-
gen species production from mitochondria [30]. This can 
account for the increased incidence of myocardial infarction 
(MI) and stroke associated with some nsNSAIDs and selec-
tive COX-2 inhibitors. An increased risk of CV AEs has 
been identified in observational studies with some NSAIDs, 
such as diclofenac [17]. While among the COX-2 inhibi-
tors, rofecoxib was associated with an increased risk of acute 
coronary syndromes, and was subsequently withdrawn from 
the therapeutic market in 2004 [31]. Non-selective NSAIDs, 
that block either COX-1 or COX-2, can also interfere with 
the production of prostaglandins that play an important role 
in maintaining renal blood flow in patients with compro-
mised renal function.
4  Non‑Steroidal Anti‑Inflammatory Drugs 
and Risk of Gastrointestinal Adverse 
Events
Non-steroidal anti-inflammatory drugs are known to 
pose a risk to the GI system, particularly nsNSAIDs, and 
COX-2 inhibitors were developed to reduce the GI AEs of 
NSAIDs. However, all NSAID regimens, including nsN-
SAIDs and COX-2 inhibitors, are found to increase upper 
GI complications (COX-2 inhibitors rate ratio [RR] = 1.81, 
95% CI 1.17–2.81; p = 0.0070; diclofenac RR = 1.89, 95% 
CI 1.16–3.09; p = 0.0106; ibuprofen RR = 3.97, 95% CI 
2.22–7.10; p < 0.0001; and naproxen RR = 4.22, 95% CI 
2.71–6.56, p < 0.0001) [32].
A meta-analysis of six RCTs with a total of 6219 patients 
revealed that COX-2 inhibitors were similar to nsNSAIDs in 
combination with the gastroprotectant proton pump inhibi-
tors in regard to upper GI AEs, GI symptoms, and CV AEs 
[33]. There was no difference in upper GI AEs between 
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Fig. 1  Actions of cyclo-oxygenase (COX) enzymes and mechanisms underlying drug-induced side effects of non-steroidal anti-inflammatory 
drugs (NSAIDs). GFR glomerular filtration rate, GI gastrointestinal, PGE2 prostaglandin E2, PGI2 prostacyclin, TXA2 thromboxane
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COX-2 inhibitors and nsNSAIDs with concurrent use of pro-
ton pump inhibitors (relative risk = 0.61, 95% CI 0.34–1.09] 
(Fig. 2). There was no significant difference in GI symp-
toms (relative risk = 1.10, 95% CI 0.88–1.39) and CV AEs 
(relative risk = 1.67, 95% CI 0.78–3.59) between the two 
groups. There was heterogeneity of the studies (p = 0.0003, 
I2 = 79%).
Gastrointestinal toxicity is an important considera-
tion when selecting an nsNSAID for elderly patients with 
arthritis. A retrospective pooled analysis of 9461 patients 
aged ≥ 65 years with OA, rheumatoid arthritis, or anky-
losing spondylitis from 21 randomized parallel-group tri-
als of ≥ 2 weeks duration with at least one celecoxib arm 
(200–400 mg/day) and one nsNSAID (naproxen, ibuprofen, 
or diclofenac) arm found celecoxib to be better tolerated 
than nsNSAIDs for GI AEs [34]. The combined incidence of 
GI AEs was reported by significantly fewer patients treated 
with celecoxib (16.7%) than naproxen (29.4%; p < 0.0001), 
ibuprofen (26.5%; p = 0.0016), or diclofenac (21.0%; 
p < 0.0001). The discontinuation rate owing to GI AEs 
was significantly lower for celecoxib (4.0%) vs. naproxen 
(8.1%; p < 0.0001) and ibuprofen (7.3%; p < 0.05), but not 
diclofenac (4.2%; p = 0.75).
5  Non‑Steroidal Anti‑Inflammatory Drugs 
and Risk of Cardiovascular Adverse Events
It was thought that the selectivity of NSAIDs for the COX-2 
enzyme may govern the CV toxicity profile, possibly owing 
to an imbalance in COX-1 and COX-2 activities. How-
ever, CV risk also exists for the nsNSAIDs, and thus CV 
toxic effects may result from differences in physiochemi-
cal properties between different NSAIDs that requires fur-
ther investigation. A meta-analysis of 26 RCTs compared 
the incidence of CV endpoints between different NSAIDs 
(Fig. 3), finding the highest risk with rofecoxib [35]. In the 
Prospective Randomized Evaluation of Celecoxib Integrated 
Safety vs Ibuprofen Or Naproxen (PRECISION) trial, 24,081 
patients were randomly assigned to celecoxib, naproxen, or 
ibuprofen for a mean treatment duration of 20 months and 
mean follow-up of 34 months [36]. Celecoxib (209 ± 37 mg) 
was non-inferior to naproxen (852 ± 103 mg) or ibuprofen 
(2045 ± 246 mg) for the primary composite outcome of CV 
death (including hemorrhagic death), non-fatal MI, or non-
fatal stroke in patients with arthritis at moderate CV risk. 
However, during the trial, 69% of all patients stopped taking 
the study drug, and the primary event rate was low: less than 
3% of patients in each treatment group in the intention-to-
treat analysis, and < 2% in the on-treatment analysis.
5.1  Non‑Steroidal Anti‑Inflammatory Drugs 
and Acute Myocardial Infarction
A population‐based cohort study was undertaken to charac-
terize the determinants, time course, and risks of acute MI 
associated with the use of oral NSAIDs in real-world use. 
The study employed a systematic review followed by a one-
stage Bayesian meta-analysis of individual patient data from 
four trials identified from database searches from inception 
to November 2013 that included five NSAIDs (ibuprofen, 
diclofenac, naproxen, celecoxib, rofecoxib) [37]. There was 
an increased risk of MI with all NSAIDs; the risk with the 
nsNSAIDs was similar, and the risk highest for rofecoxib, 
Fig. 2  Risk of upper gastrointestinal adverse events with cyclo-
oxygenase-2 inhibitors (Coxibs) vs. non-steroidal anti-inflammatory 
drugs (NSAIDs) plus proton pump inhibitor (PPI). CI confidence 
interval, M-H Mantel-Haenszel. Reproduced from Wang et  al. [33]; 
copyright permission granted by Wolters Kluwer Health Inc, 2018
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and lowest for celecoxib. The risk was greatest during the 
first month of NSAID use and with higher doses. Odds 
ratios (95% CI) for the most common current daily dose 
vs. no current exposure for individual NSAIDs are shown 
in Table 1 [37]. The OR of acute MI for current exposure 
to NSAIDs, taken for any duration of time before the index 
date, indicates an associated increase in risk of 15% for 
celecoxib (200 mg), 25% for naproxen (500 mg), 35% for 
diclofenac (100 mg), 40% for ibuprofen (1200 mg), and 55% 
for rofecoxib (25 mg). Notably, the MI risk with celecoxib 
appeared to depend on continuously using the drug for more 
than 30 days, whereas for ibuprofen, rofecoxib, diclofenac, 
and naproxen, a heightened MI risk occurred within 7 days 
of use. The absolute risk of MI associated with NSAID use 
was estimated to be about 0.5–1% per year [37]. Although 
Fig. 3  Risk of cardiovascular outcomes with all non-steroidal anti-
inflammatory drugs (NSAIDs). CV cardiovascular, MI myocardial 
infarction. Each NSAID was compared against all other NSAIDs in 
the study for each outcome. NSAIDs denoted by (*) represent statisti-
cally significant findings. Reproduced from Gunter et al. [35]; Copy-
right permission granted by John Wiley & Sons Inc, 2018
Table 1  Odds ratios (and 95% confidence interval [CI]) for the asso-
ciation between risk of myocardial infarction and common daily dose 
of individual non-steroidal anti-inflammatory drugs
Table compiled from data in Bally et al. 2017 [37]
COX-2 cyclooxygenase-2, nsNSAIDs non-selective non-steroidal anti-
inflammatory drugs
Drug Daily dose, mg Odds ratio 95% CI
nsNSAIDs
 Diclofenac 150 1.59 1.38–1.84
 Ibuprofen 1200 1.42 1.17–1.74
 Naproxen 750 1.38 1.21–1.58
COX-2 inhibitors
 Rofecoxib 25 1.54 1.43–1.66
 Celecoxib 200 1.16 1.10–1.22
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this absolute MI risk increase is small, NSAID use is very 
prevalent in older adults.
5.2  Non‑Steroidal Anti‑Inflammatory Drugs 
and Risk of Incident Heart Failure
The use of NSAIDs may be associated with an increased 
risk of heart failure (HF) as a result of salt and fluid reten-
tion secondary to the reduction in prostaglandin synthesis. 
To assess the risk of incident HF with the use of NSAIDs, a 
systematic review and meta-analysis of observational stud-
ies reporting risk ratio, OR, HR, or standardized incidence 
ratio (with 95% CI) comparing the risk of incident HF in 
NSAID users vs. non-users was conducted. The database 
searches from inception until April 2015 identified seven 
studies that included 7,543,805 participants using NSAIDs 
for any indication [38]. Use of NSAIDs was associated with 
a higher risk of developing HF, with a pooled risk ratio of 
1.17 (95% CI 1.01–1.36).
5.3  Non‑Steroidal Anti‑Inflammatory Drugs 
and Cerebrovascular Adverse Events
The use of NSAIDs may be associated with an increased 
risk of stroke, one of the major subtypes of CV disease. A 
systematic review and meta-analysis of ten observational 
case-controlled studies identified by database searches from 
inception until August 2015 has assessed the risk of hem-
orrhagic stroke associated with NSAID use for any indi-
cation [39]. As a single group, NSAID use was associated 
with a small but insignificant risk of hemorrhagic stroke 
(pooled risk ratio = 1.09, 95% CI 0.98–1.22) [Table 2]. 
However, analysis of individual NSAIDs revealed a sig-
nificantly increased risk with diclofenac (risk ratio 1.27, 
95% CI 1.02–1.59) and meloxicam (risk ratio 1.27, 95% 
CI 1.08–1.50, respectively). Inhibition of COX enzymes 
by NSAIDs could result in vasoconstriction and increased 
peripheral arterial resistance, and the inhibition of the 
COX-2 enzyme could lead to salt/fluid retention, the com-
bination of which could lead to hypertension, the prime risk 
factor for intracerebral hemorrhage. This may explain the 
significant risk observed with diclofenac and meloxicam, 
two nsNSAIDs with the highest COX-2 selectivity [40]. 
The highest risk estimate was found in rofecoxib users, 
even though the pooled risk ratio did not achieve statistical 
significance (risk ratio = 1.35, 95% CI 0.88–2.06) probably 
owing to the small number of rofecoxib users as this drug 
was withdrawn from the market in 2004 [39].
6  Non‑Steroidal Anti‑Inflammatory Drugs 
and Risk of Acute Kidney Injury
The use of NSAIDs can cause acute kidney injury (AKI) by 
inhibiting the production of prostaglandins and consequently 
reducing the blood flow to the kidneys and/or induction of 
interstitial nephritis. Acute kidney injury is a rapid and sus-
tained abruption of the renal function causing accumulation 
of waste products (e.g., urea, creatinine), which is typically 
dose and duration dependent, and reversible. Although 
patients with normal renal function are unlikely to develop 
AKI secondary to taking NSAIDs those with a history of 
hypertension, HF, or diabetes have a higher chance of devel-
oping these complications [41]. The risk of AKI is particu-
larly high in the first 30 days after initiation of therapy with 
NSAIDs. Non-steroidal anti-inflammatory drug users have 
a three-fold greater risk of developing clinical AKI com-
pared with non-NSAID users in the general population [41]. 
While the association between AKI and the use of NSAIDs 
is well known, less is known about the comparative risk of 
individual NSAIDs.
A systematic review and meta-analysis of five cohort 
studies that reported relative risk, HR, or standardized inci-
dence ratio (with 95% CI) comparing AKI risk in NSAID 
users vs. non-users was conducted. Pooled risk ratios were 
calculated for seven nsNSAIDs and two COX-2 inhibitors 
(indomethacin, piroxicam, ibuprofen, naproxen, sulindac, 
diclofenac, meloxicam, rofecoxib, and celecoxib) [42]. A 
statistically significant elevation in AKI risk was demon-
strated among most of the nsNSAIDs. Pooled risk ratios 
were fairly consistent among individual nsNSAIDs, ranging 
from 1.58 to 2.11. Differences between pooled risk ratios did 
not reach statistical significance (p ≥ 0.19 for each compari-
son). Elevated AKI risk was also observed with rofecoxib, 
Table 2  Risk ratios (and 95% confidence interval [CI]) for the asso-
ciation between risk of hemorrhagic stroke and non-steroidal anti-
inflammatory drugs (NSAIDs)
Table compiled from data in Ungprasert et al. 2016 [39]
COX-2 cyclooxygenase-2, nsNSAIDs non-selective non-steroidal anti-
inflammatory drugs
Drug Risk ratio 95% CI Heteroge-
neity, % 
(I2)
All NSAIDs 1.09 0.98–1.22 28
nsNSAIDs
 Ibuprofen 1.19 0.99–1.44 44
 Meloxicam 1.27 1.08–1.50 0
 Piroxicam 0.98 0.53–1.81 26
 Indomethacin 1.32 0.95–1.85 0
 Naproxen 1.20 0.73–1.99 82
 Diclofenac 1.27 1.02–1.59 61
COX-2 inhibitors
 Rofecoxib 1.35 0.88–2.06 9
 Celecoxib 0.90 0.66–1.22 0
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celecoxib, and two nsNSAIDs with higher COX-2 selectiv-
ity (diclofenac and meloxicam) although this did not reach 
statistical significance [32].
7  Non‑Steroidal Anti‑Inflammatory Drugs 
and Risk of Falls and Fractures
Falls and resulting fractures are a leading cause of morbid-
ity/mortality in the elderly. A nested case-control study was 
conducted using electronic medical records (2001–9) to 
determine if there was an association with fall events among 
elderly patients with OA (n = 13,354; aged 65–89 years) 
[43]. The likelihood of experiencing a fall/fracture was 
highest in patients prescribed opioid analgesics, which may 
reflect the known effects of opioids on the central nervous 
system, which is often compounded by age [44, 45]. The 
risk of falls was elevated with COX-2 inhibitors compared 
with nsNSAIDs (odds ratio = 1.3, 95% CI 1.0–1.6). A cohort 
study of exposure to analgesics in patients with OA (80% of 
cohort; n = 11,434) or RA (n = 1406) [mean age 80 years, 
85% female] found an incident rate of 26 falls with nsN-
SAIDs, 18 falls with COX-2 inhibitors, and 41 falls with 
opioids [46]. The use of COX-2 inhibitors and nsNSAIDs 
resulted in a similar risk for fracture, while fracture risk was 
elevated with opioid use (HR = 4.47, 95% CI 3.12–6.41), 
as was the risk of all-cause mortality (HR = 1.87, 95 CI 
1.39–2.53) compared with the use of nsNSAIDs. The pro-
posed mechanism for NSAID-induced bone loss entails 
altered mechano-sensing by osteocytes under circum-
stances of altered nitrous oxide production; although further 
research on this topic is needed, nitrous oxide donors such 
as isosorbide dinitrate are thought to have beneficial effects 
on bone density [47].
8  Conclusions
In this narrative literature review, we have sought to unravel 
recent data on the safety of nsNSAIDs to identify current 
understanding on the relative risk:benefit of nsNSAIDs used 
to manage pain in OA. Our key findings are summarized in 
the Panel of practice points, which is intended to assist the 
reader when making therapeutic decisions on the appropriate 
choice of medications for individual patients with OA. All 
NSAIDs have the potential for GI and CV toxicity through 
their action on the COX-1 and COX-2 enzymes. If nsN-
SAIDs are taken with a gastroprotective proton pump inhibi-
tor, the upper GI toxicity is attenuated and similar to that 
found with a COX-2-specific NSAID. There is an increased 
risk of acute MI with all NSAIDs, which may occur within 
7 days of use. The risk of incident HF is elevated with all 
NSAIDs. An increased risk of hemorrhagic stroke appears to 
be limited to the nsNSAIDs with the highest COX-2 selec-
tivity, diclofenac and meloxicam. All nsNSAIDs are associ-
ated with an increased risk of AKI. While opioid analgesics 
are associated with an increased risk of falls and fractures, 
NSAIDs are associated to a lesser extent. The excess mor-
tality observed with OA may be attributable, in part, to 
treatment algorithms including NSAIDs, paracetamol, and 
possibly COX-2 inhibitors. Consequently, multiple strate-
gies to control symptoms in OA should be considered on an 
individual patient basis.
Panel: Practice Points
All non-steroidal anti-inflammatory drugs (NSAIDs) have the poten-
tial to induce adverse events through their actions on the cyclo-
oxgygenase (COX)-1 and COX-2 enzymes, including: gastrointes-
tinal ulcers and bleeding (COX-1), hypertension and kidney injury 
(COX-1 and COX-2), and cardiovascular (CV) events [myocardial 
infarction and stroke] (COX-2 > COX-1)
The rate of upper gastrointestinal complications (ulcers and bleeding) 
is increased with all NSAIDs; the upper gastrointestinal toxicity 
of non-selective NSAIDs may be reduced by concomitant use of 
proton pump inhibitors to a level similar to that of COX-2-selective 
NSAIDs
It would appear that CV risk may be drug specific and further 
research is needed to determine the extent of NSAID-induced CV 
adverse events for both the class and individual NSAIDs. Naproxen 
does not confer better CV outcomes than other NSAIDs
There is an increased risk of myocardial infarction with all NSAIDs, 
albeit small, which can occur within 7 days of initiation of non-
selective NSAIDs
There is a higher risk of heart failure with all NSAIDs, likely as a 
result of sodium and water retention through inhibition of COX-
driven prostaglandin synthesis
There is an increased risk of stroke with certain non-selective 
NSAIDs that exhibit high COX-2 selectivity, namely diclofenac and 
meloxicam
The risk of acute kidney injury is higher among NSAID users than 
the general population, and appears to be consistently high for all 
non-selective NSAIDs
In elderly patients with osteoarthritis taking analgesics, NSAIDs are 
associated with a lower risk of falls and fractures than opioids
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